Announced
Completed
Financials
Tags
Minority
Domestic
biopharma
Biotechnology
Private Equity
United States
Single Bidder
Acquisition
Friendly
Venture Capital
biotechnology
Private
Completed
Synopsis
RA Capital Management, a multi-stage investment manager, led a $60m Series A round in Curevo Vaccine, a clinical-stage biotechnology company, focused on bringing new generation adjuvanted subunit vaccines to market, with participation from Adjuvant Capital, Janus Henderson Investors, EN Investment, and GC Pharma. “As investors primarily focused on vaccines, we were impressed by Curevo’s encouraging Phase 1 data and unique sub-unit vaccine technology platform. The opportunity to bring the first non-live varicella (chickenpox) vaccine to the global community with Curevo’s vaccine technology was also a key motivator behind our investment in the company,” Charlie Petty, Adjuvant Capital Co-Founder and Principal.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.